What does a ‘most-favored nation’ drug pricing policy look like?
And other biotech news you need to read today.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we examine the implications of President Trump’s “most-favored nation” drug-pricing decree, and the question of whether it would hold up legally. Also, we see Lux Capital attempt to attract talent with some America First-ism.
